pCPA Activity Overview

Status Total Negotiations Summary
Active Negotiations 34 Non-oncology: 21
Oncology: 13
Under Consideration for Negotiation 25 Non-oncology: 15
Oncology: 10
Completed Negotiations 619 With Letter of Intent: 530
Without agreement: 89
Negotiations That Were Not Pursued 97

pCPA Activity in the last four weeks

Activity for the last four weeks. Please note that these updates may take one to two weeks to be processed.

Engagement Letters Issued in the last four weeks

Brand Name Manufacturer Indication Engagement Date
Livtencity Takeda Canada Inc. post-transplant cytomegalovirus (CMV) infection/disease
Tecartus Gilead Sciences Canada Inc. For treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL)
Lapelga Apobiologix, a Division of Apotex Inc. To decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive antineoplastic drug.
Trurapi sanofi-aventis Canada Inc. • the treatment of patients with diabetes mellitus who require insulin for the control of hyperglycemia (normally to be used in regimens together with an intermediate or long-acting insulin) • continuous subcutaneous insulin infusion (CSII) in pump system
Ultomiris Alexion Pharma GMBH Atypical hemolytic uremic syndrome
Ultomiris Alexion Pharma Canada Corp. Paroxysmal nocturnal hemoglobinuria (PNH)
Opdivo BRISTOL-MYERS SQUIBB CANADA For the neoadjuvant treatment of adult patients with resectable NSCLC (tumours ≥4cm or node positive) when used in combination with platinum-doublet chemotherapy
Dayvigo Eisai Limited Insomnia
Kimmtrak Medison Pharma Canada Inc. For the treatment of human leukocyte antigen (HLA)-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma
"TBC" Teva Canada Inc. Treatment of: • neovascular (wet) age-related macular degeneration (AMD) • visual impairment due to diabetic macular edema (DME) • visual impairment due to macular edema secondary to retinal vein occlusion (RVO) • visual impairment due to choroidal neovas

Negotiations Completed in the last four weeks with a Letter of Intent

Brand Name Manufacturer Indication Engagement Date Close Date
Lorbrena Pfizer Canada ULC for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC)
Xpovio Forus Therapeutics Inc. For the treatment of adult patients, in combination with bortezomib (V) and dexamethasone (d), with multiple myeloma (MM) who have received at least one prior therapy.
Keytruda Merck Canada Inc. in combination with Lenvima, for the treatment of adult patients with advanced or metastatic renal cell carcinoma (RCC) with no prior systemic therapy for metastatic RCC
Qinlock Medison Pharma Canada Inc. For the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with imatinib, sunitinib, and regorafenib
Keytruda Merck Canada Inc. in combination with Lenvatinib (Lenvima) for the treatment of adult patients with advanced endometrial carcinoma that is not microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR), who have disease progression following prior platinum
Byooviz Biogen Canada Inc. Treatment of: • neovascular (wet) age-related macular degeneration (AMD) • visual impairment due to diabetic macular edema (DME) • visual impairment due to macular edema secondary to retinal vein occlusion (RVO) • visual impairment due to choroidal neovas
Lenvima Eisai Limited In combination with pembrolizumab, for the treatment of adult patients with advanced endometrial carcinoma that is not microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR), who have disease progression following prior platinum-based
Lenvima Eisai Limited In combination with pembrolizumab, for the treatment of adult patients with advanced or metastatic renal cell carcinoma (RCC) with no prior systemic therapy for metastatic renal cell carcinoma (RCC)
Jakavi Novartis Pharmaceuticals Canada Inc. acute graft-versus-host disease
Jakavi Novartis Pharmaceuticals Canada Inc. chronic graft-versus-host disease

Negotiations Completed in the last four weeks without Agreement

Brand Name Manufacturer Indication Engagement Date Close Date
Wakix Paladin Labs Inc. For the treatment of excessive daytime sleepiness or cataplexy in adult patients with narcolepsy

Negotiations that pCPA Decided Not to Pursue in the last four weeks

Brand Name Manufacturer Indication Close Date
No negotiations that pCPA decided not to pursue in the last four weeks